Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel J. Elson has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Siva Kumar Kolluri

    Cancer Research Laboratory, Department of Environmental & Molecular Toxicology, Oregon State University, Corvallis, USA

    3 shared publications
  • Alec M. Johnson

    Affiliation Department of Biology, Dr. Michael Dorrell’s Lab, Point Loma Nazarene University, San Diego, CA, United States of America

    1 shared publication
  • Allison L. Hale

    Affiliations Department of Biology, Dr. Michael Dorrell’s Lab, Point Loma Nazarene University, San Diego, CA, United States of America, Department of Biology, Dr. Heidi R. Kast-Woelbern’s Lab, Point Loma Nazarene University, San Diego, CA, United States of America

    1 shared publication
  • Amy L. Rausch

    Department of Biology, Point Loma Nazarene University, 3900 Lomaland Drive, San Diego, 92126, CA, USA

    1 shared publication
  • Bach D. Nguyen

    Cancer Research Laboratory, Department of Environmental and Molecular Toxicology Oregon State University Corvallis OR USA

    1 shared publication
  • Bridget M. Fortin

    Department of Biological Chemistry, University of California, Irvine, Irvine, USA

    1 shared publication

Latest Publications

  • Open Access

    Tumor-Suppressive Functions of the Aryl Hydrocarbon Receptor (AhR) and AhR as a Therapeutic Target in Cancer

    by Daniel J. Elson, Siva K. Kolluri

    The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor involved in regulating a wide range of biological responses. A diverse array of xenobiotics and endogenous small molecules bind to the receptor and drive unique phenotypic responses. Due in part to its role in mediating toxic responses to environmental pollutants, AhR activation has not been traditionally viewed as a viable therapeutic approach. Nonetheless, the expression and activation of AhR can inhibit the proliferation, migration, and survival of cancer cells, and many clinically approved drugs transcriptionally activate AhR. Identification of novel select modulators of AhR-regulated transcription that promote tumor suppression is an active area of investigation. The development of AhR-targeted anticancer agents requires a thorough understanding of the molecular mechanisms driving tumor suppression. Here, we summarized the tumor-suppressive mechanisms regulated by AhR with an emphasis on the endogenous functions of the receptor in opposing carcinogenesis. In multiple different cancer models, the deletion of AhR promotes increased tumorigenesis, but a precise understanding of the molecular cues and the genetic targets of AhR involved in this process is lacking. The intent of this review was to synthesize the evidence supporting AhR-dependent tumor suppression and distill insights for development of AhR-targeted cancer therapeutics.


  • The cyclin‐dependent kinase inhibitor p27Kip1 interacts with the aryl hydrocarbon receptor and negatively regulates its transcriptional activity

    by Daniel J. Elson, Bach D. Nguyen, Rhand Wood, Yi Zhang, Veronica Puig‐Sanvicens, Siva K. Kolluri

    P27Kip1 functions to coordinate cell cycle progression through the inhibition of cyclin‐dependent kinase (CDK) complexes. p27Kip1 also exerts distinct activities beyond CDK‐inhibition, including functioning as a transcriptional regulator. The aryl hydrocarbon receptor (AhR) is a ligand‐activated transcription factor with diverse biological roles. The regulatory inputs that control AhR‐mediated transcriptional responses are an active area of investigation. AhR was previously established as a direct regulator of p27Kip1 transcription. Here, we report the physical interaction of AhR and p27Kip1 and show that p27Kip1 expression negatively regulates AhR‐mediated transcription. p27Kip1 knockout cells display increased AhR nuclear localisation and significantly higher expression of AhR target genes. This work thus identifies new regulatory cross‐talk between p27Kip1 and AhR.


  • Open Access

    A novel method of screening combinations of angiostatics identifies bevacizumab and temsirolimus as synergistic inhibitors of glioma-induced angiogenesis

    by Michael I. Dorrell, Heidi R. Kast-Woelbern, Ryan T. Botts, Stephen A. Bravo, Jacob R. Tremblay, Sarah Giles, Jessica F. Wada, MaryAnn Alexander, Eric Garcia, Gabriel Villegas, et al.

    Tumor angiogenesis is critical for the growth and progression of cancer. As such, angiostasis is a treatment modality for cancer with potential utility for multiple types of cancer and fewer side effects. However, clinical success of angiostatic monotherapies has been moderate, at best, causing angiostatic treatments to lose their early luster. Previous studies demonstrated compensatory mechanisms that drive tumor vascularization despite the use of angiostatic monotherapies, as well as the potential for combination angiostatic therapies to overcome these compensatory mechanisms. We screened clinically approved angiostatics to identify specific combinations that confer potent inhibition of tumor-induced angiogenesis. We used a novel modification of theex ovochick chorioallantoic membrane (CAM) model that combined confocal and automated analyses to quantify tumor angiogenesis induced by glioblastoma tumor onplants. This model is advantageous due to its low cost and moderate throughput capabilities, while maintaining complexin vivocellular interactions that are difficult to replicatein vitro. After screening multiple combinations, we determined that glioblastoma-induced angiogenesis was significantly reduced using a combination of bevacizumab (Avastin®) and temsirolimus (Torisel®) at doses below those where neither monotherapy demonstrated activity. These preliminary results were verified extensively, with this combination therapy effective even at concentrations further reduced 10-fold with a CI value of 2.42E-5, demonstrating high levels of synergy. Thus, combining bevacizumab and temsirolimus has great potential to increase the efficacy of angiostatic therapy and lower required dosing for improved clinical success and reduced side effects in glioblastoma patients.


  • Open Access

    The Zebrafish Xenograft Models for Investigating Cancer and Cancer Therapeutics

    by John T. Gamble, Daniel J. Elson, Juliet A. Greenwood, Robyn L. Tanguay, Siva K. Kolluri

    In order to develop new cancer therapeutics, rapid, reliable, and relevant biological models are required to screen and validate drug candidates for both efficacy and safety. In recent years, the zebrafish (Danio rerio) has emerged as an excellent model organism suited for these goals. Larval fish or immunocompromised adult fish are used to engraft human cancer cells and serve as a platform for screening potential drug candidates. With zebrafish sharing ~80% of disease-related orthologous genes with humans, they provide a low cost, high-throughput alternative to mouse xenografts that is relevant to human biology. In this review, we provide background on the methods and utility of zebrafish xenograft models in cancer research.


  • Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery

    by Erin Morgan, John T. Gamble, Martin C. Pearce, Daniel J. Elson, Robert L. Tanguay, Siva Kumar Kolluri, Norbert O. Reich

    Although new cancer therapeutics are discovered at a rapid pace, lack of effective means of delivery and cancer chemoresistance thwart many of the promising therapeutics. We demonstrate a method that confronts both of these issues with the light-activated delivery of a Bcl-2 functional converting peptide, NuBCP-9, using hollow gold nanoshells. This approach has shown not only to increase the efficacy of the peptide 30-fold in vitro but also has shown to reduce paclitaxel resistant H460 lung xenograft tumor growth by 56.4%.